

Generalized Skin Disorders

Mark Sochor

Amit Pandit

William J. Brady

REFERENCES

1. Ayangco L, Rogers RS III: Oral manifestations of erythema multiforme. *Dermatol Clin* 21: 198, 2003. [PMID: 1262281]
2. French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. *Allergol Int* 55: 9 2006.
3. Mockenhaupt M: Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. *Semin Cutan Med Surg* 33: 10, 2014. [PMID: 25037254]
4. Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al: Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. *Br J Dermatol* 168: 726, 2013. [PMID: 23413807]
5. Power WJ, Ghoraiishi M, Merayo-Lloves J, et al: Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. *Ophthalmology* 102: 1669, 1995. [PMID: 9098260]
6. Weston WL, Morelli JG: Herpes simplex virus-associated erythema multiforme in pre-pubertal children. *Arch Pediatr Adolesc Med* 151: 1014, 1997. [PMID: 9343012]
7. Kakourou T, Klontza D, Soteropoulou F, Kattamis C: Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. *Eur J Pediatr* 156: 90, 1997. [PMID: 9039508]
8. Porteous DM, Berger TG: Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. *Arch Dermatol* 127: 740, 1991. [PMID: 1827245]
9. Kelemen JJ, Cioffi WG, McManus WF, et al: Burn center care for patients with toxic epidermal necrolysis. *J Am Coll Surg* 180: 273, 1995. [PMID: 7874336]
10. Roujeau JC, Kelly JP, Naldi L, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* 333: 1600, 1995. [PMID: 7477195]
11. Schöpf E, Stühmer A, Rzany B, et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. *Arch Dermatol* 127: 839, 1991. [PMID: 2036029]
12. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? *Arch Dermatol* 137: 357, 2001. [PMID: 11255340]
13. Wolkenstein P, Revuz J: Drug-induced severe skin reactions—incidence, management and prevention. *Drug Saf* 13: 56, 1995. [PMID: 8527020]
14. Tas S, Simonart T: Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome). *Dermatology* 206: 353, 2003. [PMID: 12771485]
15. Dominguez A, Cardeñosa N, Izquierdo C, et al: Prevalence of *Neisseria meningitidis* carriers in the school population of Catalonia, Spain. *Epidemiol Infect* 127: 425, 2001. [PMID: 11811875]
16. Caugant DA, Hööby EA, Magnus P, et al: Asymptomatic carriage of *Neisseria meningitidis* in a randomly sampled population. *J Clin Microbiol* 32: 323, 1994. [PMID: 8150942]
17. Anderson J, Berthelsen L, Bech Jensen B, Lind I: Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. *Epidemiol Infect* 121: 85, 1998. [PMID: 9747759]